8-K: Citius Pharmaceuticals and Citius Oncology Secure Permanent J-Code for LYMPHIR, Enhancing Patient Access

Citius Pharmaceuticals and its subsidiary Citius Oncology announced that LYMPHIR (denileukin diftitox-cxdl) has been assigned a unique, permanent J-code by the Centers for Medicare & Medicaid Services, effective April 1, 2025.

Summary

• Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid Services (CMS).
• The J-code, J9161 (Injection, denileukin diftitox-cxdl, for intravenous use, 1 microgram), will be effective from April 1, 2025.
• This J-code is expected to streamline the billing and reimbursement process for LYMPHIR, facilitating patient access.
• LYMPHIR is approved by the FDA for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million.
• Citius Pharma owns 92% of Citius Oncology.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the J-code assignment, which is a significant step for commercialization. However, the presence of a boxed warning and other safety concerns temper the overall positive outlook.

Positives

• The assignment of a permanent J-code for LYMPHIR simplifies the reimbursement process for healthcare providers.
• The J-code is expected to improve patient access to LYMPHIR.
• LYMPHIR is an FDA-approved treatment for a specific type of lymphoma.
• Management estimates the initial market for LYMPHIR currently exceeds $400 million.

Negatives

• LYMPHIR carries a boxed warning for Capillary Leak Syndrome (CLS), which can be life-threatening.
• The drug can cause serious visual impairment, infusion-related reactions, and hepatotoxicity.
• Based on findings in rats, male fertility may be compromised by treatment with LYMPHIR.

Risks

• The company's ability to commercialize LYMPHIR successfully is subject to market acceptance and competition.
• The company needs substantial additional funds to support its operations and commercialization efforts.
• There are risks associated with research and development activities, preclinical and clinical testing, and dependence on third-party suppliers.
• The company faces risks related to obtaining and maintaining financing and strategic agreements.
• LYMPHIR carries a boxed warning for Capillary Leak Syndrome (CLS), which can be life-threatening.

Future Outlook

The company anticipates that the J-code will facilitate reimbursement and improve patient access to LYMPHIR, supporting its commercialization efforts. Citius is actively engaged with the FDA to outline next steps for both programs.

Management Comments

• Leonard Mazur, Chairman and CEO of Citius Pharma and Citius Oncology, stated that the establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement.
• Leonard Mazur stated that this achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage.

Industry Context

The announcement is relevant to the pharmaceutical and oncology industries, particularly concerning treatments for cutaneous T-cell lymphoma (CTCL). The J-code assignment is expected to improve the market access and adoption of LYMPHIR, potentially impacting the competitive landscape for CTCL therapies.

Comparison to Industry Standards

• LYMPHIR competes with other therapies for CTCL, such as brentuximab vedotin (Adcetris) and mogamulizumab (Poteligeo).
• The $400 million market size estimate suggests a significant unmet need in the CTCL treatment landscape.
• The J-code assignment is a crucial step for LYMPHIR, as it simplifies reimbursement processes, similar to how other established infused therapies are handled.

Stakeholder Impact

• Shareholders may react positively to the news of the J-code assignment.
• Healthcare providers will benefit from the simplified reimbursement process.
• Patients with CTCL may have improved access to LYMPHIR as a treatment option.
• Payers (insurance companies) will need to incorporate the new J-code into their systems.

Next Steps

• Healthcare providers will begin using the permanent J-code (J9161) for LYMPHIR when submitting claims, effective April 1, 2025.
• Citius will continue to work on commercializing LYMPHIR and advancing its other pipeline products.
• Citius is actively engaged with the FDA to outline next steps for both programs.

Key Dates

Keywords

LYMPHIR, J-code, Citius Pharmaceuticals, Citius Oncology, denileukin diftitox-cxdl, CTCL, reimbursement, oncology, FDA approval, cutaneous T-cell lymphoma